Skip to main content

Table 1 Patient characteristics

From: Short-duration, submaximal intensity exercise stress combined with adenosine triphosphate decreases artifacts in myocardial perfusion single-photon emission computed tomography

  Total Group p Value
A A + 25 W A + 35 W A + 45 W
n = 109 n = 23 n = 34 n = 28 n = 24
Age, years 70 ± 10 75 ± 9 68 ± 10 69 ± 10 71 ± 8 0.056
Male, % 41 48 32 39 50 0.508
Previous MI, % 4 13 3 0 0 0.051
Previous PCI, % 16 39 12 11 4 0.051
Cerebrovascular disease, % 17 31 7 14 25 0.071
Peripheral artery disease, % 8 22 3 7 4 0.061
Hypertension, % 62 73 65 54 58 0.479
Dyslipidemia, % 57 68 62 46 54 0.051
Diabetes mellitus, % 41 46 38 46 33 0.782
Atrial fibrillation, % 5 9 3 7 0 0.445
Current Smoking, % 15 23 15 11 13 0.715
Laboratory data
Hb, g/dL 13.6 ± 1.7 12.7 ± 1.7 13.6 ± 1.4 14.1 ± 1.9 13.9 ± 1.8 0.051
HbA1c, % 7.8 ± 2.6 6.7 ± 1.2 8.2 ± 2.7 8.4 ± 3.2 7.4 ± 2.5 0.216
UA, mg/dL 5.4 ± 1.5 5.1 ± 0.8 5.2 ± 1.5 5.8 ± 1.8 5.6 ± 1.8 0.415
LDL-C, mg/dL 122 ± 35 108 ± 29 122 ± 30 139 ± 35 113 ± 41 0.036
HDL-C, mg/dL 54 ± 26 53 ± 15 61 ± 41 51 ± 10 48 ± 20 0.493
Creatinine, mg/dL 0.92 ± 0.64 1.23 ± 1.15 0.77 ± 0.21 0.81 ± 0.37 0.97 ± 0.45 0.054
BNP, pg/mL 49 (22, 78) 58 (22, 208) 48 (23, 68) 59 (15, 65) 40 (11, 63) 0.067
Medications
ADA, % 22 14 27 29 17 0.167
ATA, % 22 36 27 11 17 0.192
β blocker, % 14 14 18 18 4 0.440
CCB, % 46 55 47 46 38 0.634
Diuretics, % 8 14 6 11 4 0.374
Nitrates, % 7 14 9 7 0 0.636
RAS-I, % 37 36 27 36 54 0.075
Statin, % 41 57 44 21 42 0.462
  1. Data are mean ± SD or percentage except for BNP level (median, 25–75%)
  2. MI myocardial infarction, PCI percutaneous coronary intervention, Hb hemoglobin, UA uric acid, LDL-C low-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol, BNP brain natriuretic peptide, ADA antidiabetic agents, ATA antithrombotic agents, CCB calcium-channel blocker, RAS-I renin-angiotensin system inhibitor